Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mater Sci Eng C Mater Biol Appl ; 135: 112695, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35581070

RESUMO

In the present study we developed an injectable, bioactive and degradable hydrogel composed of alginate at 2.5% oxidation degree and calcium-activated platelet rich plasma (PRP) for wound healing applications (PRP-HG-2.5%). The alginate gives mechanical support to the hydrogel while the activated PRP provides growth factors that enhance wound healing and fibrin which creates an adequate microenvironment for cell migration and proliferation. The rheological and mechanical properties of the hydrogel were characterized. Further characterization revealed that PRP-HG-2.5% showed a faster hydrolitic degradation rate than unmodified alginate and a similar platelet derived growth factor (PDGF-BB) release profile. In vitro efficacy studies, carried out in human fibroblasts and keratinocytes, showed that PRP-HG-2.5% was not cytotoxic and that it was able to promote cell adhesion and proliferation. Thereafter, in an in vivo full thickness wound healing study conducted in diabetic mice, no differences were found among PRP-HG-2.5% and its counterpart without PRP, likely due to the xenogeneic origin of the PRP. This hypothesis was validated in vitro, since a cytotoxic effect was observed after human PRP application to mouse fibroblasts. Therefore, PRP-HG-2.5% might be a promising strategy for chronic woundstreatment, although its effectiveness should be evaluated in a more reliable preclinical model.


Assuntos
Diabetes Mellitus Experimental , Plasma Rico em Plaquetas , Alginatos , Animais , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/terapia , Fibrina/metabolismo , Fibrina/farmacologia , Humanos , Hidrogéis/metabolismo , Hidrogéis/farmacologia , Camundongos , Plasma Rico em Plaquetas/metabolismo , Cicatrização
2.
Nanomedicine ; 18: 101-111, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30849549

RESUMO

The usefulness of nanotechnology to increase the bioavailability of drugs and decrease their toxicity may be a tool to deal with multiresistant P. aeruginosa (Mr-Pa) respiratory infections. We describe the preparation and the in vivo efficacy and safety of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) by the pulmonary and intramuscular routes. Nanoparticles showed 1-2 mg/L minimum inhibitory concentration against eight extensively drug-resistant P. aeruginosa strains. In vivo, SCM-NLC displayed significantly lower CFU/g lung than the saline and similar to that of the free SCM, even the dose in SCM-NLC group was lower than free SCM. There was no tissue damage related to the treatments. Biodistribution assessments showed a mild systemic absorption after nebulization and a notorious absorption after IM route. Altogether, it could be concluded that SCM-NLC were effective against P. aeruginosa in vivo, not toxic and distribute efficiently to the lung and liver after pulmonary or intramuscular administrations.


Assuntos
Colistina/análogos & derivados , Portadores de Fármacos/química , Lipídeos/química , Pulmão/microbiologia , Nanoestruturas/química , Pseudomonas aeruginosa/efeitos dos fármacos , Animais , Colistina/administração & dosagem , Colistina/efeitos adversos , Colistina/farmacologia , Feminino , Inflamação/patologia , Injeções Intramusculares , Pulmão/patologia , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Nanoestruturas/toxicidade , Nanoestruturas/ultraestrutura , Distribuição Tecidual/efeitos dos fármacos , Testes de Toxicidade , Resultado do Tratamento
3.
Int J Pharm ; 556: 320-329, 2019 Feb 10.
Artigo em Inglês | MEDLINE | ID: mdl-30553008

RESUMO

Electrospun nanofibrous dressings present suitable characteristics to be used in wound healing, such as high porosity and high surface area-to-volume ratio. In this study, a wound dressing based on PLGA and Aloe vera containing lipid nanoparticles (NLCs) was developed. NLCs were added in order to add a lipid component that could avoid the adhesion of the dressing to the wound and improve its handling. Membranes with and without NLCs were composed of uniform fibers of about 1 µm in diameter. Their porosity was above 80% and their thickness was about 160 µm. Both dressings showed similar water vapour transmission rate 1100 g/m2day. The formulation containing NLCs presented a higher ultimate tensile strength (2.61 ±â€¯0.46 MPa) and a higher water uptake. Both formulations were biocompatible in vitro. Furthermore, the cell adhesion assay demonstrated that both membranes had a low adherence profile, although it was lower with the dressing containing NLCs. Finally, their efficacy was evaluated in a full thickness wound healing assay conducted in db/db mice, where both enhanced healing similarly. Accordingly, the PLGA-AV-NLC membrane might be a promising strategy for the treatment of chronic wounds, since it improved handling in comparison to the formulation without NLCs.


Assuntos
Aloe/química , Nanofibras , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química , Cicatrização/efeitos dos fármacos , Animais , Bandagens , Adesão Celular , Química Farmacêutica/métodos , Modelos Animais de Doenças , Lipídeos/química , Masculino , Camundongos , Nanopartículas , Porosidade , Resistência à Tração , Água/química
4.
J Control Release ; 197: 41-7, 2015 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-25449803

RESUMO

The development of an effective treatment able to reduce the healing time of chronic wounds is a major health care need. In this regard, our research group has recently demonstrated the in vivo effectiveness of the topical administration of rhEGF-loaded lipid nanoparticles in healing-impaired db/db mice. Here we report the effectiveness of rhEGF-NLC (rhEGF loaded nanostructured lipid carriers) in a more relevant preclinical model of wound healing, the porcine full-thickness excisional wound model. The rhEGF-NLC showed a particle size of around 335nm, negative surface charge (-27mV) and a high encapsulation efficiency of 94%. rhEGF plasma levels were almost undetectable, suggesting that no systemic absorption occurred, which may minimise potential side effects and improve treatment safety. In vivo healing experiments carried out in large white pigs demonstrated that 20µg of rhEGF-NLC topically administered twice a week increased the wound closure and percentage of healed wounds by day 25, compared with the same number of intralesional administrations of 75µg free rhEGF and empty NLC. Moreover, rhEGF-NLC improved the wound healing quality expressed in terms of number of arranged microvasculature, fibroblast migration and proliferation, collagen deposition and evolution of the inflammatory response. Overall, these findings demonstrated that topically administered rhEGF-NLC may generate de novo intact skin after full thickness injury in a porcine model, thereby confirming their potential clinical application for the treatment of chronic wounds.


Assuntos
Portadores de Fármacos/administração & dosagem , Fator de Crescimento Epidérmico/administração & dosagem , Lipídeos/administração & dosagem , Nanoestruturas/administração & dosagem , Cicatrização/efeitos dos fármacos , Administração Tópica , Animais , Modelos Animais de Doenças , Feminino , Neovascularização Fisiológica , Proteínas Recombinantes/administração & dosagem , Pele/lesões , Pele/patologia , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...